Table of Content

1. Key Insights

2. Biliary Tract Cancer (BTC): Market Overview at a Glance
2.1. Market Share (%) Distribution of BTC in 2017
2.2. Market Share (%) Distribution of BTC in 2030

3. Executive Summary

4. Organizations

5. Biliary tract cancer (BTC): Disease Background and Overview
5.1. Introduction
5.2. Classification of Cholangiocarcinomas
5.3. Staging
5.3.1. Intrahepatic CCA (iCCA)
5.3.2. Perihilar CCA
5.3.3. Distal extrahepatic
5.3.4. Gall Bladder Cancer
5.4. Symptoms
5.5. Etiology
5.6. Pathogenesis
5.7. Biomarkers
5.8. Diagnosis
5.8.1. Diagnosis of Intrahepatic CCA
5.8.2. Diagnosis of Perihilar and Distal CCA
5.8.3. Diagnosis of Gall Bladder Cancer
5.8.4. Guidelines for the diagnosis of intrahepatic cholangiocarcinoma
5.8.5. ESMO Clinical Practice Guidelines for diagnosis for Biliary tract Cancer

6. Epidemiology and Patient Population
6.1. Key Findings
6.2. 7MM Total Incident Patient Population of BTC
6.3. Assumptions and Rationale: 7MM
6.4. United States Epidemiology
6.4.1. Total Incident Cases of Biliary tract cancers (BTC) in the United States
6.4.2. Age-specific Cases of Biliary tract cancers (BTC) in the United States
6.4.3. Mutation-specific Cases of Biliary tract cancers (BTC) in the United States
6.4.4. Stage-specific Cases of Biliary tract cancers (BTC) in the United States
6.5. Germany Epidemiology
6.5.1. Total Incident Cases of Biliary tract cancers (BTC) in Germany
6.5.2. Age-specific Cases of Biliary tract cancers (BTC) in Germany
6.5.3. Mutation-specific Cases of Biliary tract cancers (BTC) in Germany
6.5.4. Stage-specific Cases of Biliary tract cancers (BTC) in Germany
6.6. France Epidemiology
6.6.1. Total Incident Cases of Biliary tract cancers (BTC) in France
6.6.2. Age-specific Cases of Biliary tract cancers (BTC) in France
6.6.3. Mutation-specific Cases of Biliary tract cancers (BTC) in France
6.6.4. Stage-specific Cases of Biliary tract cancers (BTC) in France
6.7. Italy Epidemiology
6.7.1. Total Incident Cases of Biliary tract cancers (BTC) in Italy
6.7.2. Age-specific Cases of Biliary tract cancers (BTC) in Italy
6.7.3. Mutation-specific Cases of Biliary tract cancers (BTC) in Italy
6.7.4. Stage-specific Cases of Biliary tract cancers (BTC) in Italy
6.8. Spain Epidemiology
6.8.1. Total Incident Cases of Biliary tract cancers (BTC) in Spain
6.8.2. Age-specific Cases of Biliary tract cancers (BTC) in Spain
6.8.3. Mutation-specific Cases of Biliary tract cancers (BTC) in Spain
6.8.4. Stage-specific Cases of Biliary tract cancers (BTC) in Spain
6.9. UK Epidemiology
6.9.1. Total Incident Cases of Biliary tract cancers (BTC) in UK
6.9.2. Age-specific Cases of Biliary tract cancers (BTC) in UK
6.9.3. Mutation-specific Cases of Biliary tract cancers (BTC) in UK
6.9.4. Stage-specific Cases of Biliary tract cancers (BTC) in UK
6.10. Japan Epidemiology
6.10.1. Total Incident Cases of Biliary tract cancers (BTC) in Japan
6.10.2. Age-specific Cases of Biliary tract cancers (BTC) in Japan
6.10.3. Mutation-specific Cases of Biliary tract cancers (BTC) in Japan
6.10.4. Stage-specific Cases of Biliary tract cancers (BTC) in Japan

7. Therapies and Treatment strategies
7.1.1. Treatment Recommendations – British Society of Gastroenterology guidelines
7.1.2. Guidelines for the treatment of Intrahepatic Cholangiocarcinoma
7.1.3. ESMO Clinical Practice Guidelines for Treatment and Follow-up for Biliary Tract Cancer
7.1.4. NCCN Guidelines for Hepatobiliary Cancer 2020
7.1.5. Treatment Algorithm

8. Patient Journey

9. Research Priorities

10. Unmet Needs

11. Marketed Drugs
11.1. Pemigatinib: Incyte Corporation
11.1.1. Drug Description
11.1.2. Regulatory Approval
11.1.3. Other Developmental Activities
11.1.4. Clinical Development
11.1.5. Safety and Efficacy
11.1.6. Product Profile
11.2. Larotrectinib: Loxo Oncology/Bayer
11.2.1. Drug Description
11.2.2. Regulatory Approval
11.2.3. Other Developmental Activities
11.2.4. Clinical Development
11.2.5. Safety and Efficacy
11.2.6. Product Profile
11.3. Entrectinib: Roche
11.3.1. Product Description
11.3.2. Regulatory Approval
11.3.3. Other Developmental Activities
11.3.4. Clinical Development
11.3.5. Safety and Efficacy
11.3.6. Product Profile

12. Emerging Therapies
12.1.1. Key cross competition
12.2. Ivosidenib: Agios Pharmaceuticals
12.2.1. Product Description
12.2.2. Other Developmental Activities
12.2.3. Clinical Development
12.2.4. Safety and Efficacy
12.2.5. Product Profile
12.3. Infigratinib: QED Therapeutics
12.3.1. Drug Description
12.3.2. Other Developmental Activities
12.3.3. Clinical Development
12.3.4. Safety and Efficacy
12.3.5. Product Profile
12.4. Melphalan: Delcath Systems
12.4.1. Drug Description
12.4.2. Other Developmental Activities
12.4.3. Clinical Development
12.4.4. Safety and Efficacy
12.4.5. Product Profile
12.5. Derazantinib: Basilea Pharmaceutica
12.5.1. Drug Description
12.5.2. Other Developmental Activities
12.5.3. Clinical Development
12.5.4. Safety and Efficacy
12.5.5. Product Profile
12.6. Regorafenib: Bayer
12.6.1. Drug Description
12.6.2. Other Developmental Activities
12.6.3. Clinical Development
12.6.4. Safety and Efficacy
12.6.5. Product Profile
12.7. Erdafitinib: Janssen Pharmaceutical
12.7.1. Product Description
12.7.2. Other Developmental Activities
12.7.3. Clinical Development
12.7.4. Safety and Efficacy
12.7.5. Product Profile
12.8. Opaganib: RedHill Biopharma
12.8.1. Product Description
12.8.2. Other Developmental Activities
12.8.3. Clinical Development
12.8.4. Safety and Efficacy
12.8.5. Product Profile
12.9. Fimaporfin: PCI biotech
12.9.1. Product Description
12.9.2. Other Developmental Activities
12.9.3. Clinical Development
12.9.4. Safety and Efficacy
12.9.5. Product Profile
12.10. KA2507: Karus Therapeutics
12.10.1. Product Description
12.10.2. Clinical Development
12.10.3. Safety and Efficacy
12.10.4. Product Profile
12.11. Lenvatinib: Eisai
12.11.1. Product Description
12.11.2. Other Developmental Activities
12.11.3. Clinical Development
12.11.4. Safety and Efficacy
12.11.5. Product Profile
12.12. Telotristat ethyl: Lexicon Pharmaceuticals/TerSera Therapeutics
12.12.1. Product Description
12.12.2. Other Developmental Activities
12.12.3. Clinical Development
12.12.4. Safety and Efficacy
12.12.5. Product Profile
12.13. DKN-01: Leap Therapeutics
12.13.1. Product Description
12.13.2. Other Developmental Activities
12.13.3. Clinical Development
12.13.4. Safety and Efficacy
12.13.5. Product Profile
12.14. Niraparib (Zejula): GlaxoSmithKline
12.14.1. Product Description
12.14.2. Other Developmental Activities
12.14.3. Clinical Development
12.14.4. Product Profile
12.15. E7090: Eisai
12.15.1. Product Description
12.15.2. Other Developmental Activities
12.15.3. Clinical Development
12.15.4. Safety and Efficacy
12.15.5. Product Profile
12.16. A166: KLUS Pharma
12.16.1. Product Description
12.16.2. Clinical Development
12.16.3. Safety and Efficacy
12.16.4. Product Profile
12.17. Durvalumab: AstraZeneca
12.17.1. Product Description
12.17.2. Other developmental activities
12.17.3. Clinical Development
12.17.4. Safety and Efficacy
12.17.5. Product Profile
12.18. Pembrolizumab: Merck Sharp & Dohme Corp.
12.18.1. Product description
12.18.2. Other development activities
12.18.3. Clinical development
12.18.4. Safety and Efficacy
12.18.5. Product Profile
12.19. Futibatinib: Taiho Oncology
12.19.1. Drug Description
12.19.2. Other Developmental Activities
12.19.3. Clinical Development
12.19.4. Safety and Efficacy
12.19.5. Product Profile
12.20. Nab-paclitaxel: Celgene
12.20.1. Product description
12.20.2. Other Development Activities
12.20.3. Clinical Development
12.20.4. Safety and Efficacy
12.20.5. Product Profile
12.21. Surufatinib: Hutchison Medipharma Limited
12.21.1. Product Description
12.21.2. Clinical Development
12.21.3. Safety and Efficacy
12.21.4. Product Profile
12.22. Bintrafusp Alfa: Merck Sharp & Dohme Corp.
12.22.1. Product Description
12.22.2. Other Developmental Activities
12.22.3. Clinical Development
12.22.4. Safety and Efficacy
12.22.5. Product Profile
12.23. Entinostat: Syndax Pharmaceuticals
12.23.1. Product Description
12.23.2. Clinical development
12.23.3. Product Profile
12.24. Zanidatamab: BeiGene
12.24.1. Product Description
12.24.2. Other Developmental Activities
12.24.3. Clinical Development
12.24.4. Safety and Efficacy
12.24.5. Product Profile
12.25. Nivolumab: Bristol-Myers Squibb
12.25.1. Product Description
12.25.2. Other Developmental Activities
12.25.3. Clinical Development
12.25.4. Safety and Efficacy
12.25.5. Product Profile
12.26. TAS 102: Taiho Pharma
12.26.1. Product Description
12.26.2. Other Developmental Activities
12.26.3. Clinical Development
12.26.4. Safety and Efficacy
12.26.5. Product Profile
12.27. Nanoliposomal irinotecan: Ipsen
12.27.1. Product Description
12.27.2. Other Developmental Activities
12.27.3. Clinical Development
12.27.4. Safety and Efficacy
12.27.5. Product Profile
12.28. Trastuzumab deruxtecan (T-DXd): Daiichi Sankyo
12.28.1. Product Description
12.28.2. Other Developmental Activities
12.28.3. Clinical Development
12.28.4. Safety and Efficacy
12.28.5. Product Profile
12.29. NUC-1031: NuCana
12.29.1. Product Description
12.29.2. Other Developmental Activities
12.29.3. Clinical Development
12.29.4. Safety and Efficacy
12.29.5. Product Profile

13. Biliary Tract Cancer: Market Outlook
13.1. Key Findings
13.2. Market Size of BTC in 7MM

14. Market Outlook: 7MM
14.1. United States Market Size
14.1.1. Total Market size of BTC in the US
14.1.2. Market Size by Therapies for Early Stage Disease
14.1.3. Market Size by Therapies in First-line Advanced and Metastatic Cases
14.1.4. Market Size by Therapies in Second-line Advanced and Metastatic Cases
14.2. Germany Market Size
14.2.1. Total Market size of BTC in Germany
14.2.2. Market Size by Therapies for Early Stage Disease
14.2.3. Market Size by Therapies in First-line Advanced and Metastatic Cases
14.2.4. Market Size by Therapies in Second-line Advanced and Metastatic Cases
14.3. France Market Size
14.3.1. Total Market size of BTC in France
14.3.2. Market Size by Therapies for Early Stage Disease
14.3.3. Market Size by Therapies in First-line Advanced and Metastatic Cases
14.3.4. Market Size by Therapies in Second-line Advanced and Metastatic Cases
14.4. Italy Market Size
14.4.1. Total Market size of BTC in Italy
14.4.2. Market Size by Therapies for Early Stage Disease
14.4.3. Market Size by Therapies in First-line Advanced and Metastatic Cases
14.4.4. Market Size by Therapies in Second-line Advanced and Metastatic Cases
14.5. Spain Market Size
14.5.1. Total Market size of BTC in Spain
14.5.2. Market Size by Therapies for Early Stage Disease
14.5.3. Market Size by Therapies in First-line Advanced and Metastatic Cases
14.5.4. Market Size by Therapies in Second-line Advanced and Metastatic Cases
14.6. UK Market Size
14.6.1. Total Market size of BTC in UK
14.6.2. Market Size by Therapies for Early Stage Disease
14.6.3. Market Size by Therapies in First-line Advanced and Metastatic Cases
14.6.4. Market Size by Therapies in Second-line Advanced and Metastatic Cases
14.7. Japan Market Size
14.7.1. Total Market size of BTC in Japan
14.7.2. Market Size by Therapies for Early Stage Disease
14.7.3. Market Size by Therapies in First-line Advanced and Metastatic Cases
14.7.4. Market Size by Therapies in Second-line Advanced and Metastatic Cases

15. Market Drivers

16. Market Barriers

17. Reimbursement and Market Access

18. SWOT Analysis

19. Case studies
19.1. A Case Report of Intrahepatic Cholangiocarcinoma in a Young Male
19.2. A new potential immunotherapy drug for solid tumor: A case study
19.3. A case of distal extrahepatic cholangiocarcinoma with two positive resection margins

20. KOL Views
21. Appendix
22. Report Methodology
23. DelveInsight Capabilities
24. Disclaimer
25. About DelveInsight



List of Figures


Figure 1: Risk factors and molecular alterations of BTC
Figure 2: Possible Risk Factor and Symptoms
Figure 3: Cells of origin in Cholangiocarcinoma (CCA)
Figure 4: Chronic Inflammation Cycle
Figure 5: Components of the tumor microenvironment in CCA
Figure 6: Factors secreted by cancer-associated fibroblasts
Figure 7: Intracellular pathways involved in CCA proliferation and apoptosis
Figure 8: Common driver genes in HCC and CCA
Figure 9: Molecular genetics of BTC
Figure 10: Algorithm for management and diagnosis of intrahepatic CCA
Figure 11: Algorithm for management and diagnosis of perihilar cholangiocarcinoma
Figure 12: Total Cases of Biliary tract cancers (BTC) in the 7MM (2017–2030)
Figure 13: Total Incident Cases of BTC in the US (2017–2030)
Figure 14: Age-specific Cases of BTC in the US (2017–2030)
Figure 15: Mutation-specific Cases of BTC in the US (2017–2030)
Figure 16: Stage-specific Cases of BTC in the US (2017–2030)
Figure 17: Total Incident Cases of BTC in Germany (2017–2030)
Figure 18: Age-specific Cases of BTC in Germany (2017–2030)
Figure 19: Mutation-specific Cases of BTC in Germany (2017–2030)
Figure 20: Stage-specific Cases of BTC in Germany (2017–2030)
Figure 21: Total Incident Cases of BTC in France (2017–2030)
Figure 22: Age-specific Cases of BTC in France (2017–2030)
Figure 23: Mutation-specific Cases of BTC in France (2017–2030)
Figure 24: Stage-specific Cases of BTC in France (2017–2030)
Figure 25: Total Incident Cases of BTC in Italy (2017–2030)
Figure 26: Age-specific Cases of BTC in Italy (2017–2030)
Figure 27: Mutation-specific Cases of BTC in Italy (2017–2030)
Figure 28: Stage-specific Cases of BTC in Italy (2017–2030)
Figure 29: Total Incident Cases of BTC in Spain (2017–2030)
Figure 30: Age-specific Cases of BTC in Spain (2017–2030)
Figure 31: Mutation-specific Cases of BTC in Spain (2017–2030)
Figure 32: Stage-specific Cases of BTC in Spain (2017–2030)
Figure 33: Total Incident Cases of BTC in UK (2017–2030)
Figure 34: Age-specific Cases of BTC in UK (2017–2030)
Figure 35: Mutation-specific Cases of BTC in UK (2017–2030)
Figure 36: Stage-specific Cases of BTC in UK (2017–2030)
Figure 37: Total Incident Cases of BTC in Japan (2017–2030)
Figure 38: Age-specific Cases of BTC in Japan (2017–2030)
Figure 39: Mutation-specific Cases of BTC in Japan (2017–2030)
Figure 40: Stage-specific Cases of BTC in Japan (2017–2030)
Figure 41: Algorithm for diagnosis and management of Biliary Tract Cancer
Figure 42: A suggested algorithm for the diagnosis and Treatment of cholangiocarcinomas
Figure 43: A suggested treatment algorithm for patients with iCCA
Figure 44: Algorithm for diagnosis and management of dCCA
Figure 45: Flowchart – Management and treatment of patients suspected of perihilar CCA
Figure 46: A suggested diagnosis and treatment algorithm for Gallbladder Cancer
Figure 47: Unmet Needs of Cholangiocarcinoma (CCA)
Figure 48: 7 Major Market Size of BTC in USD Million (2017–2030)
Figure 49: Market Size of BTC in the US, USD Millions (2017–2030)
Figure 50: Market Size by Therapies for Early Stage Disease in the US in USD Million (2017–2030)
Figure 51: Market Size of BTC by First Line in the US in USD Million (2017–2030)
Figure 52: Market Size of BTC by Second Line in the US in USD Million (2017–2030)
Figure 53: Market Size of BTC in Germany, USD Millions (2017–2030)
Figure 54: Market Size for Early Stage Disease in Germany in USD Million (2017–2030)
Figure 55: Market Size of BTC by First Line in Germany in USD Million (2017–2030)
Figure 56: Market Size of BTC by Second Line in Germany in USD Million (2017–2030)
Figure 57: Market Size of BTC in France, USD Millions (2017–2030)
Figure 58: Market Size by Therapies for Early Stage Disease in France in USD Million (2017–2030)
Figure 59: Market Size of BTC by First Line in France in USD Million (2017–2030)
Figure 60: Market Size of BTC by Second Line in France in USD Million (2017–2030)
Figure 61: Market Size of BTC in Italy, USD Millions (2017–2030)
Figure 62: Market Size by Therapies for Early Stage Disease in Italy in USD Million (2017–2030)
Figure 63: Market Size of BTC by First Line in Italy in USD Million (2017–2030)
Figure 64: Market Size of BTC by Second Line in Italy in USD Million (2017–2030)
Figure 65: Market Size of BTC in Spain, USD Millions (2017–2030)
Figure 66: Market Size by Therapies for Early Stage Disease in Spain in USD Million (2017–2030)
Figure 67: Market Size of BTC by First Line in Spain in USD Million (2017–2030)
Figure 68: Market Size of BTC by Second Line in Spain in USD Million (2017–2030)
Figure 69: Market Size of BTC in UK, USD Millions (2017–2030)
Figure 70: Market Size by Therapies for Early Stage Disease in UK in USD Million (2017–2030)
Figure 71: Market Size of BTC by First Line in UK in USD Million (2017–2030)
Figure 72: Market Size of BTC by Second Line in UK in USD Million (2017–2030)
Figure 73: Market Size of BTC in Japan, USD Millions (2017–2030)
Figure 74: Market Size by Therapies for Early Stage Disease in Japan in USD Million (2017–2030)
Figure 75: Market Size of BTC by First Line in Japan in USD Million (2017–2030)
Figure 76: Market Size of BTC by Second Line in Japan in USD Million (2017–2030)
Figure 77: Market Drivers
Figure 78:Market Barriers
Figure 79: SWOT Analysis of Biliary Tract Cancer


List of Tables


Table 1: TNM and AJCC/ UICC Staging Systems for iCCA
Table 2: AJCC staging of iCCA: Comparison of 7th and 8th editions
Table 3: TNM and AJCC/UICC Staging Systems for Perihilar and Distal CCA
Table 4: TNM and AJCC/UICC Staging Systems for Gall Bladder Cancer
Table 5: Risk Factors for BTC
Table 6: Host genetic polymorphism associated with cholangiocarcinoma
Table 7: Recommendations of ICCA for Diagnosis
Table 8: ESMO Clinical Practice Guidelines for treatment and follow-up
Table 9: Total Incident Cases of Biliary tract cancers in the 7MM (2017–2030)
Table 10: Total Incident Cases of BTC in the US (2017–2030)
Table 11: Age-specific Cases of BTC in the US (2017–2030)
Table 12: Mutation-specific Cases of BTC in the US (2017–2030)
Table 13: Stage-specific Cases of BTC in the US (2017–2030)
Table 14: Total Incident Cases of BTC in Germany (2017–2030)
Table 15: Age-specific Cases of BTC in Germany (2017–2030)
Table 16: Mutation-specific Cases of BTC in Germany (2017–2030)
Table 17: Stage-specific Cases of BTC in Germany (2017–2030)
Table 18: Total Incident Cases of BTC in France (2017–2030)
Table 19: Age-specific Cases of BTC in France (2017–2030)
Table 20: Mutation-specific Cases of BTC in France (2017–2030)
Table 21: Stage-specific Cases of BTC in France (2017–2030)
Table 22: Total Incident Cases of BTC in Italy (2017–2030)
Table 23: Age-specific Cases of BTC in Italy (2017–2030)
Table 24: Mutation-specific Cases of BTC in Italy (2017–2030)
Table 25: Stage-specific Cases of BTC in Italy (2017–2030)
Table 26: Total Incident Cases of BTC in Spain (2017–2030)
Table 27: Age-specific Cases of BTC in Spain (2017–2030)
Table 28: Mutation-specific Cases of BTC in Spain (2017–2030)
Table 29: Stage-specific Cases of BTC in Spain (2017–2030)
Table 30: Total Incident Cases of BTC in UK (2017–2030)
Table 31: Age-specific Cases of BTC in UK (2017–2030)
Table 32: Mutation-specific Cases of BTC in UK (2017–2030)
Table 33: Stage-specific Cases of BTC in UK (2017–2030)
Table 34: Total Incident Cases of BTC in Japan (2017–2030)
Table 35: Age-specific Cases of BTC in Japan (2017–2030)
Table 36: Mutation-specific Cases of BTC in Japan (2017–2030)
Table 37: Stage-specific Cases of BTC in Japan (2017–2030)
Table 38: Recommendations of the British Society of Gastroenterology guidelines
Table 39: Recommendations of iCCA for management
Table 40: Levels of evidence and grades of recommendation
Table 41: ESMO Clinical Practice Guidelines for treatment and follow-up
Table 42: ESMO Clinical Practice Guidelines for treatment and follow-up
Table 43: NCCN Guidelines for Hepatobiliary Cancer 2020
Table:44 NCCN Guidelines for Principles of Systemic Therapy**
Table 45:: INCB054828, Clinical Trial Description, 2020
Table 46: Larotrectinib, Clinical Trial Description, 2020
Table 47: Entrectinib, Clinical Trial Description, 2020
Table 48: Key Cross: Emerging Therapies (III& II/III)
Table 49: Key Cross: Emerging Therapies (II& I/II)
Table 50: AG-120, Clinical Trial Description, 2020
Table 51: BGJ398, Clinical Trial Description, 2020
Table 52: Melphalan/HDS, Clinical Trial Description, 2020
Table 53: Derazantinib, Clinical Trial Description, 2020
Table 54: Regorafenib, Clinical Trial Description, 2020
Table 55: Erdafitinib, Clinical Trial Description, 2020
Table 56: Opaganib, Clinical Trial Description, 2020
Table 57: Fimaporfin; Clinical Trial Description, 2020
Table 58: KA2507; Clinical Trial Description, 2020
Table 59: Lenvatinib; Clinical Trial Description, 2020
Table 60 Telotristat ethyl; Clinical Trial Description, 2020
Table 61 DKN-01; Clinical Trial Description, 2020
Table 62: Niraparib Clinical Trial Description, 2020
Table 63: E7090, Clinical Trial Description, 2020
Table 64: A166, Clinical Trial Description, 2020
Table 65: Durvalumab, Clinical Trial Description, 2020
Table: 66 Pembrolizumab, Clinical Trial Description, 2020
Table 67: Futibatinib, Clinical Trial Description, 2020
Table 68: Bintrafusp Alfa, Clinical Trial Description, 2020
Table 69: Entinostat, Clinical Trial Description, 2020
Table 70: Zanidatamab, Clinical Trial Description, 2020
Table 71: Nivolumab, Clinical Trial Description, 2020
Table 72: TAS-102 Clinical Trial Description, 2020
Table 73: Nanoliposomal irinotecan, Clinical Trial Description, 2020
Table 74: T-DXd, Clinical Trial Description, 2020
Table 75: NUC-1031, Clinical Trial Description, 2020
Table 76: Seven Major Market Size of BTC in USD Million (2017–2030)
Table 77: The US Market Size of BTC in USD Million (2017–2030)
Table 78: Market Size by Therapies for Early Stage Disease in the US in USD Million (2017–2030)
Table 79: Market Size of BTC by First Line in the US in USD Million (2017–2030)
Table 80: Market Size of BTC by Second Line in the US in USD Million (2017–2030)
Table 81: Germany Market Size of BTC in USD Million (2017–2030)
Table 82: Market Size by Therapies for Early Stage Disease in Germany in USD Million (2017–2030)
Table 83: Market Size of BTC by First Line in Germany in USD Million (2017–2030)
Table 84: Market Size of BTC by Second Line in Germany in USD Million (2017–2030)
Table 85: France Market Size of BTC in USD Million (2017–2030)
Table 86: Market Size by Therapies for Early Stage Disease in France in USD Million (2017–2030)
Table 87: Market Size of BTC by First Line in France in USD Million (2017–2030)
Table 88: Market Size of BTC by Second Line in France in USD Million (2017–2030)
Table 89: Italy Market Size of BTC in USD Million (2017–2030)
Table 90: Market Size by Therapies for Early Stage Disease in Italy in USD Million (2017–2030)
Table 91: Market Size of BTC by First Line in Italy in USD Million (2017–2030)
Table 92: Market Size of BTC by Second Line in Italy in USD Million (2017–2030)
Table 93: Spain Market Size of BTC in USD Million (2017–2030)
Table 94: Market Size by Therapies for Early Stage Disease in Spain in USD Million (2017–2030)
Table 95: Market Size of BTC by First Line in Spain in USD Million (2017–2030)
Table 96: Market Size of BTC by Second Line in Spain in USD Million (2017–2030)
Table 97: UK Market Size of BTC in USD Million (2017–2030)
Table 98: Market Size by Therapies for Early Stage Disease in UK in USD Million (2017–2030)
Table 99: Market Size of BTC by First Line in UK in USD Million (2017–2030)
Table 100: Market Size of BTC by Second Line in UK in USD Million (2017–2030)
Table 101: Japan Market Size of BTC in USD Million (2017–2030)
Table 102: Market Size by Therapies for Early Stage Disease in Japan in USD Million (2017–2030)
Table 103: Market Size of BTC by First Line in Japan in USD Million (2017–2030)
Table 104:Market Size of BTC by Second Line in Japan in USD Million (2017–2030)